{"id":"topical-suspension-vehicle","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Topical suspension vehicles are inert or minimally active formulation bases used to suspend solid particles or active pharmaceutical ingredients for application to the skin or mucous membranes. They facilitate uniform distribution, absorption, and retention of therapeutic agents at the site of application while providing appropriate viscosity, stability, and skin compatibility.","oneSentence":"A topical suspension vehicle is a pharmaceutical formulation designed to deliver active ingredients to the skin surface through a liquid suspension base.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:13:15.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vehicle/excipient for topical dermatological formulations"}]},"trialDetails":[{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT01188928","phase":"PHASE3","title":"LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-09","conditions":"Psoriasis Vulgaris","enrollment":1152},{"nctId":"NCT04490109","phase":"PHASE2","title":"B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis","status":"COMPLETED","sponsor":"AOBiome LLC","startDate":"2020-06-24","conditions":"Atopic Dermatitis, Pruritus","enrollment":547},{"nctId":"NCT06128369","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery","status":"TERMINATED","sponsor":"Oculis","startDate":"2023-12-18","conditions":"Inflammation Eye, Pain, Postoperative, Cataract","enrollment":117},{"nctId":"NCT04219358","phase":"PHASE1","title":"Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-03-23","conditions":"Actinic Cheilitis","enrollment":49},{"nctId":"NCT03235024","phase":"PHASE2","title":"Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"AOBiome LLC","startDate":"2018-01-15","conditions":"Atopic Dermatitis Eczema","enrollment":122},{"nctId":"NCT03590366","phase":"PHASE2","title":"A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea","status":"COMPLETED","sponsor":"AOBiome LLC","startDate":"2018-07-02","conditions":"Rosacea","enrollment":140},{"nctId":"NCT02998840","phase":"PHASE2","title":"A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure","status":"COMPLETED","sponsor":"AOBiome LLC","startDate":"2016-11","conditions":"Prehypertension, Hypertension, Stage I","enrollment":132},{"nctId":"NCT00804193","phase":"NA","title":"Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2004-06","conditions":"Tinea Pedis","enrollment":553},{"nctId":"NCT02485704","phase":"PHASE3","title":"Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies","status":"COMPLETED","sponsor":"ParaPRO LLC","startDate":"2017-05-10","conditions":"Scabies","enrollment":280},{"nctId":"NCT02485717","phase":"PHASE3","title":"Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies","status":"COMPLETED","sponsor":"ParaPRO LLC","startDate":"2017-05-02","conditions":"Scabies","enrollment":291},{"nctId":"NCT02723539","phase":"PHASE1","title":"A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI","status":"COMPLETED","sponsor":"Microbion Corporation","startDate":"2017-03-06","conditions":"Diabetic Foot Infection","enrollment":52},{"nctId":"NCT03880357","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2018-10-22","conditions":"Scalp Psoriasis","enrollment":485},{"nctId":"NCT03122353","phase":"PHASE1","title":"BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Tolmar Inc.","startDate":"2017-04-11","conditions":"Scalp Psoriasis","enrollment":699},{"nctId":"NCT01977781","phase":"PHASE1","title":"Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2013-12","conditions":"Ocular GVHD","enrollment":40},{"nctId":"NCT02644551","phase":"PHASE2","title":"The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis","status":"UNKNOWN","sponsor":"9305-9954 Quebec Inc","startDate":"2016-11","conditions":"Onychomycosis","enrollment":120},{"nctId":"NCT01064830","phase":"PHASE2","title":"Topical Cyclosporine Suspension for the Treatment of Brittle Nails","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-02","conditions":"Brittle Nail Syndrome","enrollment":21},{"nctId":"NCT01535599","phase":"PHASE3","title":"Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-03","conditions":"Acute Otitis Externa","enrollment":768},{"nctId":"NCT01535560","phase":"PHASE3","title":"Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-04","conditions":"Acute Otitis Externa","enrollment":589},{"nctId":"NCT01426854","phase":"PHASE3","title":"Nepafenac Compared to Placebo for Ocular Pain and Inflammation","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-07","conditions":"Cataract","enrollment":260},{"nctId":"NCT01060072","phase":"PHASE3","title":"Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-02","conditions":"Inflammation, Pain","enrollment":407},{"nctId":"NCT01238783","phase":"PHASE2","title":"Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2011-01","conditions":"Bacterial Conjunctivitis","enrollment":""},{"nctId":"NCT00420628","phase":"PHASE4","title":"Pediatric Zylet Safety and Efficacy Study","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Chalazion, Hordeolum","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle","TolaSure Vehicle Gel","Placebo"],"phase":"marketed","status":"active","brandName":"Topical suspension vehicle","genericName":"Topical suspension vehicle","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A topical suspension vehicle is a pharmaceutical formulation designed to deliver active ingredients to the skin surface through a liquid suspension base. Used for Vehicle/excipient for topical dermatological formulations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}